Latest Breaking News On - ஜநரல் நிதி விதிகள் - Page 5 : comparemela.com

Lt Governor delegates financial powers to more officers

Covid-19 vaccine: Who owns the IP rights to Bharat Biotech's publicly funded Covaxin?

A woman being vaccinated in Ahmedabad. | Reuters/Amit Dave On Saturday, the pharmaceutical company Bharat Biotech officially announced the sale prices for its Covid-19 vaccine, Covaxin. State governments will have to pay Rs 600 per dose while private hospitals will have to pay Rs 1,200 per dose. These prices, fixed far above the corresponding rates announced by the Serum Institute of India for its vaccine, Covishield, has surprised observers for many reasons. The Serum Institute could cite royalty payments to the Swedish-Britsh firm AstraZeneca from which it has licensed its vaccine as a potential reason for higher prices. But Bharat Biotech does not have to pay any royalty for Covaxin. Covaxin is, in large measure, a product of publicly funded research in India.

Nearly 140 deptts to switch over to e-office by middle of June this year

Nearly 140 deptts to switch over to e-office by middle of June this year Nearly 140 deptts to switch over to e-office by middle of June this year Directions issued for immediate assessment of IT infra Mohinder Verma JAMMU, Apr 24: In order to ensure transparency and accountability, the Government of Union Territory of Jammu and Kashmir has directed nearly 140 departments to switch over to e-office as the only mode of transaction of business by middle of June this year. This practice was adopted in all the offices in the Civil Secretariat few days back and in the next phase focus will be on offices at the district level.

(OCGN), Astrazeneca PLC (NYSE:AZN) - Ocugen's Partner Bharat Biotech Ramping Manufacturing To Produce 700M COVID-19 Vaccine Doses Annually

Serum, Bharat Biotech to get suppliers' credit for 300 mn Covid-19 doses